Sugar Analogs and 5-Fluorouridine in Combination Chemotherapy

  • Dietrich Keppler
  • Axel Holstege
  • Gisbert Weckbecker


One of the possible approaches to tumor chemotherapy involves the elimination of the malignant cells by means of cytostatic or cytocidal drugs that should be as selective as possible for a given tumor. The comparatively high degree of selective toxicity induced by the antibacterial chemotherapeutic agents has not been achieved with the antitumor drugs since their selectivity must be based on minor metabolic differences between the normal and the malignant cells and tissues. Many of the effective drugs in cancer chemotherapy are antimetabolites that inhibit enzymes of essential metabolic pathways on the basis of a structural similarity with physiological intermediates, interfering thereby with cellular growth and proliferation. This may be exemplified by the blockade of thymidylate synthase (EC by 5-f luorodeoxyuridine 5’-monophosphate, a metabolite of the pyrimidine analogs 5-fluorouracil, 5-f luorodeoxyuridine, or 5-fluorouridine (1). Inhibition of thymidylate synthase can lead to a depletion of thymine nucleotides and result in DNA synthesis inhibition due to substrate deficiency.


Hepatoma Cell Pyrimidine Synthesis Morris Hepatoma Substrate Deficiency Uridine Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. Heidelberger, P. V. Danenberg, and R. G. Moran, Fluorinated Pyrimidines and Their Nucleosides, Adv. Enzymol. 54: 57 (1983).Google Scholar
  2. 2.
    T. Anukarahanonta, A. Holstege, and D. Keppler, Selective Enhancement of 5-Fluorouridine Uptake and Action in Rat Hepatomas in vivo Following Pretreatment with D-Calactosamine and 6-Azauridine or N-(Phosphonoacetyl)-L-aspartate, Eur. J. Cancer 16: 1171 (1980).PubMedGoogle Scholar
  3. 3.
    D. Keppler, J. Fauler, T. Gasser, A. Holstege, K. Leube, C. SchulzHolstege, and G. Weckbecker, Uridylate-trapping Sugar Analogs in Combination with Inhibitors of Uridylate Synthesis de novo and 5Fluorouridine, Adv. Enz. Reg. 23: 61 (1985).CrossRefGoogle Scholar
  4. 4.
    A. Holstege and D. Keppler, Effects of D-Glucosamine and 6-Azauridine on Nucleotide Contents, 5-Fluorouridine Uptake, and Cytotoxicity in TA3 Mammary Tumor Cells, J. Nat. Cancer Inst., in press (1986).Google Scholar
  5. 5.
    D. F. Smith, E. F. Walborg, Jr., and J. P. Chang, Establishment of a Transplantable Ascites Variant of a Rat Hepatoma Induced by 3’Methyl-4-dimethylaminoazobenzene, Cancer Res. 30: 2306 (1970).PubMedGoogle Scholar
  6. 6.
    D. Keppler, Uridine Triphosphate Deficiency, Growth Inhibition, and Death in Ascites Hepatoma Cells Induced by a Combination of Pyrimidine Biosynthesis Inhibition with Uridylate Trapping, Cancer Res. 37: 911 (1977).PubMedGoogle Scholar
  7. 7.
    A. Holstege, C. Schulz-Holstege, K. A. Reif fen, F. Schneider, and D. Keppler, Uridylate Trapping Induced by the C-2-Modified D-Glucose Analogs Glucosone, Fluoroglucose, and Glucosamine, Eur. J. Biochem. 121: 469 (1982).PubMedCrossRefGoogle Scholar
  8. 8.
    D. Keppler and W. Kaiser, Enzymatic Analysis of Guanine Nucleotides in Tissues and Cells, Anal. Biochem. 86: 147 (1978).Google Scholar
  9. 9.
    G. Weckbecker and D. Keppler, Substrate Properties of 5-Fluorouridine Diphospho Sugars Detected in Hepatoma Cells, Biochem. Pharm. 33: 2291 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    D. Keppler, C. Schulz-Holstege, J. Fauler, K. A. Reiffen, and F. Schneider, Uridylate Trapping, Induction of UTP Deficiency, and Stimulation of Pyrimidine Synthesis De Novo by D-Galactosone, Biochem. J. 206: 139 (1982).PubMedGoogle Scholar
  11. 11.
    S. Bayne, Aldosuloses (Osones), in: “Methods in Carbohydrate Chemistry,” Volume 2, R. L. Whistler and M. L. Wolf rom, eds., Academic Press, New York (1963).Google Scholar
  12. 12.
    D. Keppler, J. Pausch, and K. Decker, Selective Uridine Triphosphate Deficiency Induced by D-Galactosamine in Liver and Reversed by Pyrimidine Nucleotide Precursors. Effect on Ribonucleic Acid Synthesis, J. Biol. Chem. 249: 211 (1974).PubMedGoogle Scholar
  13. 13.
    K. Decker and D. Keppler, Galactosamine Hepatitis: Key Role of the Nucleotide Deficiency Period in the Pathogenesis of Cell Injury and Cell Death, Rev. Physiol. Biochem. Pharmacol. 71: 77 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    R. C. Jackson, J. C. Williams, and G. Weber, Enzyme Pattern-directed Chemotherapy: Synergistic Interaction of 3-Deazauridine with DGalactosamine, Cancer Treat. Rep. 60: 835 (1976).PubMedGoogle Scholar
  15. 15.
    W. Reutter and C. Bauer, Terminal Sugars in Glycoconjugates: Metabolism of Free and Protein-bound L-Fucose, N-Acetyl-neuraminic Acid and D-Galactose in Liver and Morris Hepatomas, in: “Morris Hepatomas,” H. P. Morris and W. E. Criss, eds., Plenum Press, New York (1978).Google Scholar
  16. 16.
    G. Weber, Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: G. H. A. Clowes Memorial Lecture, Cancer Res. 43: 3466 (1983).PubMedGoogle Scholar
  17. 17.
    E. P. Anderson and R. W. Brockman, Feedback Inhibition of Uridine Kinase by Cytidine Triphosphate and Uridine Triphosphate, Biochim. Biophys. Acta. 91: 380 (1964).PubMedGoogle Scholar
  18. 18.
    D. Keppler and A. Holstege, Pyrimidine Nucleotide Metabolism and its Compartmentation, in: “Metabolic Compartmentation,” H. Sies, ed., Academic Press, London (1982).Google Scholar
  19. 19.
    A. Holstege, B. Herrmann, and D. Keppler, Increased Formation of Nucleotide Derivatives of 5-Fluorouridine in Hepatoma Cells Treated with Inhibitors of Pyrimidine Synthesis and D-Galactosamine, FEBS Lett. 95: 361 (1978).PubMedCrossRefGoogle Scholar
  20. 20.
    A. L. Pogolotti, Jr., P. A. Nolan, and D. V. Santi, Methods for the Complete Analysis of 5-Fluorouracil Metabolites in Cell Extracts, Anal. Biochem. 117: 178 (1981).PubMedCrossRefGoogle Scholar
  21. 21.
    J. Pausch, A. Holstege, T. Anukarahanonta, D. Keppler, and W. Gerok, First Clinical Experiences with a Selective Chemotherapy of Hepatocellular Carcinoma with 5-Fluorouridine in Combination with other Antipyrimidines, Adv. Enz. Reg. 24: 429 (1986).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Dietrich Keppler
    • 1
  • Axel Holstege
    • 1
  • Gisbert Weckbecker
    • 1
  1. 1.Biochemisches InstitutUniversity of Freiburg im BreisgauFreiburg i. Br.West Germany

Personalised recommendations